. 2020 May 30;18:117. doi: 10.1186/s12957-020-01893-w

Table 3.

Odds ratios and 95% confidence intervals of distant metastasis across different breast cancer subtypes. Association of clinicopathological variables with distant metastasis was analyzed using univariable binary logistic regression

Variables	Category	Overall (N = 1059)			Luminal A (N = .485)			Luminal B (N = 122)			Her2-enriched (N = 170)			TNBC (N = 282)
		Overall (N = 1059)			Luminal (N = 607)						Non-luminal (N = 452)
		OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value	OR	95% CI	P value
Age (years)	≤ 40	1.773	1.262–2.493	0.001	2.283	1.321–3.953	0.003	1.255	0.440–3.584	0.670	2.037	0.901-4.608	0.087	1.333	0.730–2.433	0.348
Age (years)	> 40	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Menarche	≤ 12	0.946	0.656–1.364	0.767	0.998	0.567–1.758	0.995	2.571	0.931–7.092	0.068	0.824	0.327–2.075	0.681	0.620	0.309–1.245	0.180
Menarche	> 12	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Menopause	≤ 50	0.626	0.409–0.957	0.030	0.792	0.423–1.482	0.466	0.939	0.317–2.783	0.317	0.451	0.143–1.426	0.175	0.401	0.166–0.967	0.042
Menopause	> 50	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Parity	Nulliparity	1.301	0.817–2.071	0.268	1.049	0.553–1.993	0.883	5.385	0.680–42.66	0.111	2.069	0.444–9.646	0.269	1.037	0.441–2.439	0.934
Parity	Multiparity	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Breastfeeding	Yes	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Breastfeeding	No	1.108	0.780–1.572	0.567	1.170	0.702–1.950	0.546	2.685	0.741–9.729	0.149	1.095	0.433–2.772	0.848	1.329	0.696–2.544	0.388
BMI	≥ 25	0.832	0.623–1.110	0.603	1.064	0.699–1.619	0.774	0.913	0.381–2.189	0.935	0.415	0.188–0.915	0.029	0.782	0.449–1.362	0.385
BMI	< 25	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Family history	Yes	1.061	0.747–1.511	0.785	1.153	0.659–2.018	0.659	2.342	0.859–6.410	0.096	1.169	0.511–2.674	0.711	0.968	0.500–1.873	0.922
Family history	No	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Grade	I–II	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Grade	III	1.174	0.822–1.678	0.378	0.993	0.605–1.627	0.976	1.398	0.430–4.546	0.578	1.708	0.607–4.802	0.310	1.273	0.627–2.583	0.504
Stage	I–II	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Stage	III	1.883	1.373–2.646	< 0.0001	2.160	1.377–3.389	0.001	1.156	0.439–3.039	0769	2.227	0.949–5.208	0.066	1.616	0.863–3.021	0.134
Tumor size	≤ 5	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Tumor size	> 5	1.115	0.829–1.501	0.472	0.886	0.582–1350	0.969	2.068	0.716–5.971	0.179	1.985	0.897–4.389	0.091	0.978	0.543–1.762	0.940
T	T1–2	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
	T3–4	1.429	1.015–2.012	0.041	1.162	0.732–1.845	0.525	1.605	0.498–5.169	0.428	2.440	0.948–6.276	0.064	1.624	0.768–3.345	0.204
	T1–3	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
	T4	2.115	1.544–2.898	< 0.0001	2.685	1.649–4.371	< 0.0001	2.380	0.964–5.876	0.060	1.569	0.708–3.478	0.267	1.709	0.957–3.054	0.070
N	N0	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
N	N1–3	1.855	1.319–2.611	< 0.0001	2.571	1.548–4.274	< 0.0001	0.807	0.300–2169	0.671	1.736	0.704–4.292	0231	1.515	0.797–2.882	0.205
Chemotherapy	Anthracycline	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Chemotherapy	Anthracycline-taxane	0.510	0.355–0.766	0.001	0.417	0.226–0.769	0.005	0.629	0.228–1.734	0.370	0.769	0.329–1.798	0.544	0.518	0.237–1.131	0.099
Radiotherapy	Yes	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Radiotherapy	No	1.788	1.269–2.521	0.001	1.923	1.160–3.187	0.011	0.861	0.322–2.303	0.766	2.304	0.984–5.398	0.055	1.794	0.898–3.585	0.098
Surgery	MRM	Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref		Ref	Ref
Surgery	BCT	1.005	0.624–1.618	0.995	0.837	0.414–1.694	0.621	0.996	0.254–3902	0.995	1.242	0.368–4.190	0727	1.175	0.464–2.977	0.734

Ref reference, OR odd ratio, CI confidence interval, TNBC triple negative breast cancer, BMI body mass index, T primary tumor size, N involved lymph nodes